← All trials
NCT03986294
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2019
- Primary completion
- Jan 1, 2022
- Completion date
- Jan 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 122
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of AmsterdamLead sponsor
- Maastricht UniversityCollaborator
- Utrecht UniversityCollaborator
- Isala Clinics, Zwolle, The NetherlandsCollaborator
- University of AmsterdamReponsible party - principal investigator
- Medical University of ViennaCollaborator
- Vall d'Hebron Institute of Research, Galatea ClinicCollaborator
- University of VeronaCollaborator
- University of AmsterdamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.